Drug intelligence / Profile preview

CT040

Development stage: Preclinical
Lead developer: Clover Therapeutics

Overview

CT040 is a preclinical therapeutic candidate being developed by Clover Therapeutics. While the specific biological target, molecular modality, and primary indication have not been publicly disclosed, Clover Therapeutics focuses on developing genetics-driven treatments for ophthalmic conditions, particularly age-related macular degeneration (AMD). The program is part of a pipeline derived from the company's research into the genetic drivers of vision loss, utilizing data from their DIVERSITY and PROGRESSION observational studies to identify novel drug targets.

Beyond the preview

Go deeper on CT040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT040.

Explore the full profile